HSP90AA1 and neoplasm: In sum, we demonstrate a higher pre-clinical efficacy with dual HSF-HSP90 pathway inhibition in an autochthonous mouse colonic tumor model in vivo and confirm that in this synergistic context, HSP90 inhibitors are promising cancer drugs with strong tumor selectivity.